Common antioxidant may guard against liver disease, says CU Anschutz researcher
(University of Colorado Anschutz Medical Campus) A common antioxidant found in human breast milk and foods like kiwi fruit can protect against nonalcoholic fatty liver disease (NAFLD) in the offspring of obese mice, according to researchers at the University of Colorado Anschutz Medical Campus.
ConclusionsSurgery imitating ESG combined with CY-09 reduces body weight, improves insulin resistance and alleviates hepatic steatosis. The combination therapy may be a promising method for treating obesity and NAFLD.
CONCLUSIONS These results indicate that GDLP against T2DM-induced hepatic steatosis, oxidative stress, and inflammation by improving the Nrf2/HO-1 signaling pathway in db/db mice, suggesting the GDLP may serve as an effective strategy for in fatty liver treatment. PMID: 32245940 [PubMed - as supplied by publisher]
In this study, we have revealed that mice fed CDAHFD showed significantly lowerd serum total cholesterol and triglyceride (TG) levels, in addition to reduced body weight (BW). Furthermore, hepatic microsomal triglyceride transfer protein (MTP) expression was significantly downregulated in CDAHFD-fed mice. Thus, the current CDAHFD-fed mouse model has points that are distinct from human NAFLD/NASH, in general, which is based upon abdominal obesity. PMID: 32238704 [PubMed - in process]
Condition: Non-alcoholic Fatty Liver Disease (NAFLD) Interventions: Drug: Metabolic Cofactor Supplementation; Drug: Sorbitol Sponsors: ScandiBio Therapeutics AB; Koç University; Koç University Hospital; Göteborg University; Sahlgrenska University Hospital, Sweden; KTH Royal Institute of Technology; University of Helsinki; Helsinki University Central Hospital; Monitor CRO Recruiting
Conclusions: The prevalence of suspected NAFLD continues to increase in Korean adolescents.Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; KNHANES, Korea National Health and Nutrition Examination Survey; NAFLD, non-alcoholic fatty liver disease. PMID: 32223545 [PubMed - as supplied by publisher]
AbstractUrsodeoxycholic acid (UDCA) is a secondary bile acid that is used to treat primary biliary cholangitis. Although UDCA has a hepatoprotective effect in some diseases, its benefit in nonalcoholic fatty liver disease (NAFLD) remains controversial. We aimed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of UDCA in overweight subjects with elevated liver enzymes after multiple administrations of UDCA and compare these changes with vitamin E treatment. Overweight subjects (body mass index, 25 ‐30 kg/m2) with elevated alanine aminotransferase (ALT) level (40 ‐200 IU/L) were enrolled. Subject...
We present an up-to-date systematic review of the current literature regarding the safety in artificial and natural sweeteners use as a means of weight loss or diabetes control.Expert opinion: Natural sweeteners have not been associated directly with NAFLD, and on the contrary, some, such as stevia, and trehalose, may have a protective effect. Rare sugars and polyols can be used safely and have significant benefits that include anti-oxidant effect and optimal glycemic control. Artificial sweeteners, due to their effect on NAFLD development and insulin resistance, are not indicated in patients with obesity or diabetes. Furt...
AbstractIntroductionInsulin resistance (IR) plays a central role in pathogenesis of nonalcoholic steatohepatitis (NASH). The aim of this study was to correlate histopathological grading and IR in overweight/obese patients with NASH as compared with lean NASH.MethodsPatients with NASH who underwent liver biopsy between January 2012 and December 2012 were included. Anthropometric, clinical, and biochemical features, necro-inflammatory grades, and fibrosis stage on liver biopsies were scored according to Brunt and non-alcoholic fatty liver disease (NAFLD) activity score (NAS).ResultsOf 42 patients, 33 (78.6%) had body mass in...
Publication date: Available online 23 March 2020Source: Pharmacological ResearchAuthor(s): Helda Tutunchi, Alireza Ostadrahimi, Maryam Saghafi-Asl, Mohammad-Javad Hosseinzadeh-Attar, Abolhasan Shakeri, Mohammad Asghari-Jafarabadi, Neda Roshanravan, Nazila Farrin, Mohammad Naemi, Milad Hasankhani
Publication date: Available online 12 March 2020Source: Hepatobiliary &Pancreatic Diseases InternationalAuthor(s): Li-Ming Wu, Hui He, Gang Chen, Yu Kuang, Bing-Yi Lin, Xin-Hua Chen, Shu-Sen Zheng